BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology 2014;3:e956012. [PMID: 25941588 DOI: 10.4161/21624011.2014.956012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Recondo G, Mezquita L. Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. Future Oncol 2020;16:1659-64. [PMID: 32783513 DOI: 10.2217/fon-2020-0707] [Reference Citation Analysis]
2 Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol 2020;16:1767-91. [PMID: 32564612 DOI: 10.2217/fon-2020-0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wagner SC, Ichim TE, Bogin V, Min WP, Silva F, Patel AN, Kesari S. Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine. Oncotarget 2017;8:28595-613. [PMID: 28404894 DOI: 10.18632/oncotarget.15563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Hayes DA, Kunde DA, Taylor RL, Pyecroft SB, Sohal SS, Snow ET. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One 2017;12:e0177919. [PMID: 28591206 DOI: 10.1371/journal.pone.0177919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) 2015;3:519-43. [PMID: 26350593 DOI: 10.3390/vaccines3030519] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
6 Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res 2019;25:3495-507. [PMID: 30804020 DOI: 10.1158/1078-0432.CCR-18-3997] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
7 Zhang N, Chang Y, Rios A, An Z. HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin (Shanghai) 2016;48:39-48. [PMID: 26496898 DOI: 10.1093/abbs/gmv103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
8 Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology 2020;9:1818437. [PMID: 33117602 DOI: 10.1080/2162402X.2020.1818437] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21:1128-1138. [PMID: 26444637 DOI: 10.1038/nm.3944] [Cited by in Crossref: 182] [Cited by in F6Publishing: 173] [Article Influence: 30.3] [Reference Citation Analysis]
10 Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother 2015;11:1368-86. [PMID: 25874884 DOI: 10.1080/21645515.2015.1026495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ye P, Wang Y, Li R, Chen W, Wan L, Cai P. The HER family as therapeutic targets in colorectal cancer. Crit Rev Oncol Hematol 2022;:103681. [PMID: 35462030 DOI: 10.1016/j.critrevonc.2022.103681] [Reference Citation Analysis]
12 Mansouri-Fard S, Ghaedi M, Shokri MR, Bahadori T, Khoshnoodi J, Golsaz-Shirazi F, Jeddi-Tehrani M, Amiri MM, Shokri F. Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines. Asian Pac J Cancer Prev 2020;21:439-47. [PMID: 32102522 DOI: 10.31557/APJCP.2020.21.2.439] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Black LE, Longo JF, Carroll SL. Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. Am J Pathol 2019;189:1898-912. [PMID: 31351986 DOI: 10.1016/j.ajpath.2019.06.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
14 Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT. HER3 signaling and targeted therapy in cancer. Oncol Rev 2018;12:355. [PMID: 30057690 DOI: 10.4081/oncol.2018.355] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
15 Zhu L, Yuan P, Zhao Z, Wang X, Wang G, Yan L. [Bacterial expression of 183-227aa region of HER3 extracellular domain I and preparation and identification of its polyclonal antibodies]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:806-13. [PMID: 32895213 DOI: 10.12122/j.issn.1673-4254.2020.06.06] [Reference Citation Analysis]
16 Jin D, Yu X, Chen B, Li Z, Ding J, Zhao X, Qi G. Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model. Immunotherapy 2017;9:537-53. [PMID: 28509606 DOI: 10.2217/imt-2017-0004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Chung YW, Kim S, Hong JH, Lee JK, Lee NW, Lee YS, Song JY. Overexpression of HER2/HER3 and clinical feature of ovarian cancer. J Gynecol Oncol 2019;30:e75. [PMID: 31328457 DOI: 10.3802/jgo.2019.30.e75] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]